Annette Bauer-Brandl
Overview
Explore the profile of Annette Bauer-Brandl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holzem F, Mikkelsen R, Schaffland J, Stillhart C, Brandl M, Bauer-Brandl A
J Pharm Sci
. 2024 Dec;
114(2):1485-1494.
PMID: 39730032
Physiological and artificial solubilizing agents usually enhance apparent solubility of poorly soluble drugs, and in many cases also oral drug exposure. However, exposure may decrease in cases where micellization reduces...
2.
Eriksen J, Milsmann J, Brandl M, Bauer-Brandl A
J Pharm Sci
. 2024 Dec;
114(2):1376-1384.
PMID: 39694273
For compendial dissolution testing of solid dosage forms, media volumes of 500 to 900 mL are used in apparatus I and II to ensure sink conditions. However, these volumes are...
3.
Czajkowski M, Slaba A, Milanowski B, Bauer-Brandl A, Brandl M, Skupin-Mrugalska P
Eur J Pharm Sci
. 2024 Oct;
203:106936.
PMID: 39414171
In the current study, it was demonstrated that three commercially available grades of hydrogenated phospholipids (HPL) differing in their content of phosphatidylcholine may be used as components for hot melt-extruded...
4.
Holzem F, Parrott N, Schaffland J, Brandl M, Bauer-Brandl A, Stillhart C
J Pharm Sci
. 2024 Jul;
113(10):3054-3064.
PMID: 39059554
Enabling drug formulations are often required to ensure sufficient absorption after oral administration of poorly soluble drugs. While these formulations typically increase the apparent solubility of the drug, it is...
5.
Paulus F, Holm R, Stappaerts J, Bauer-Brandl A
Eur J Pharm Sci
. 2024 Apr;
197:106765.
PMID: 38608735
Lipid-based formulations (LBFs) are an enabling-formulation approach for lipophilic poorly water-soluble compounds. In LBFs, drugs are commonly pre-dissolved in lipids, and/or surfactants/cosolvents, hereby avoiding the rate-limiting dissolution step. According to...
6.
Guidetti M, Hilfiker R, Kuentz M, Bauer-Brandl A, Blatter F
Eur J Pharm Sci
. 2024 Feb;
195:106722.
PMID: 38336250
Posaconazole is a broad-spectrum antifungal agent exhibiting rich polymorphism. Up to now, a total of fourteen different crystal forms have been reported, sometimes with an ambiguous nomenclature, but less is...
7.
Holzem F, Schaffland J, Brandl M, Bauer-Brandl A, Stillhart C
Eur J Pharm Sci
. 2024 Jan;
194:106703.
PMID: 38224722
Predicting the absorption of drugs from enabling formulations is still challenging due to the limited capabilities of standard physiologically based biopharmaceutics models (PBBMs) to capture complex absorption processes. Amongst others,...
8.
Paulus F, Bauer-Brandl A, Stappaerts J, Holm R
Eur J Pharm Sci
. 2023 Nov;
192:106634.
PMID: 37951315
Enabling formulations, such as lipid-based formulations (LBFs), are means to deliver challenging-to-formulate, poorly soluble drugs. LBFs may be composed of lipids, surfactants and/or cosolvents and can be classified depending on...
9.
Raines K, Agarwal P, Augustijns P, Alayoubi A, Attia L, Bauer-Brandl A, et al.
AAPS J
. 2023 Nov;
25(6):103.
PMID: 37936002
The in-person workshop "Drug Dissolution in Oral Drug Absorption" was held on May 23-24, 2023, in Baltimore, MD, USA. The workshop was organized into lectures and breakout sessions. Three common...
10.
Czajkowski M, Jacobsen A, Bauer-Brandl A, Brandl M, Skupin-Mrugalska P
Int J Pharm
. 2023 Aug;
644:123294.
PMID: 37544387
Amorphous solid dispersions (ASD) represent a viable formulation strategy to improve dissolution and bioavailability of poorly soluble drugs. Our study aimed to evaluate the feasibility and potential role of hydrogenated...